Antisense & RNAi Therapeutics Market Is Witnessing Significant Growth Due To Introduction Of Technological Advancements In Drug Delivery Till 2025
The
global antisense and RNAi therapeutics market size is
expected to reach USD 1.81 billion by 2025, according to a new report by Grand
View Research, Inc., recording an 8.6% CAGR during the forecast period. Rising
instances of external funding to conduct clinical studies pertaining to
introduction of novel drug moieties plays a vital role in the process of new
product development. This fuels market growth.
Multinational
healthcare establishments promote awareness and aid in finding novel therapies
for treatment of different disorders. Private institutes such as California
Institute of Regenerative Medicine and ALS Association are involved in
conducting trials by funding research institutes and pharmaceutical
organizations and this is expected to significantly fuel sector growth.
Moreover, government initiatives for speeding the development of drug delivery
platforms in order to reduce disease burden are attributive for industrial
growth.
Antisense
and RNAi therapeutics services are applicable in treatment of a wide range of
diseases that target nucleic acid and affect cell growth cycle. miRNA is attracting
considerable interest in its ability to restore gene expression and correct
protein production, thereby influencing industrial progress. Developments that
involve the research of using different routes to deliver the desired effect of
candidate moiety before its removal from blood are anticipated to fuel sector
growth.
However,
challenges associated with drug delivery are expected to impede growth to a
certain extent. Delivery technologies that enable mitigation of off-target
effects and undesirable immunological stimulation need to be introduced in
order to reduce the effect of restraining factors.
Browse full
research report on Antisense & RNAi Therapeutics Market:
www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
Further
key findings from the report suggest:
- RNA interference technology accounted for the
largest share in market revenue in 2016 owing to advantages associated
with this technology over antisense technology
- Based on the triggering of RNA molecules this
technology is segmented into siRNA and miRNA. Owing to significant
involvement of miRNA in maintaining a cell’s identity, these are used to
provide deep insight into cancer metastasis. siRNA is highly specific and
allows induction at advanced stages of cancer growth as compared to
chemotherapy. This has resulted in attaining the largest share in oncology
applications
- Usage of RNAi therapy to selectively target
SNPs in genetic disorders will provide this segment a number of potential
treatment avenues over the forecast period
- Extensive R&D programs carried out to
develop an efficient method for delivery of RNA silencing therapeutic
products is anticipated to propel growth. These R&D programs are based
on obtaining desired pharmacological action prior to removal of the
product from the cytoplasm and systemic circulation
- Isis Pharmaceuticals/ Ionis Pharmaceuticals,
GSK, Alnylam Pharmaceuticals, Marina Biosciences, Sanofi-Genzyme, Quark
Pharmaceuticals, Gene Signal, and Benitec Biopharma are major companies in
the market involved in development and commercialization of products
- Strong product portfolio in different phases of
clinical trials and preclinical development programs is expected to
contribute to the growth of this industry.
Browse more
reports of this category by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global antisense and RNAi
therapeutics market on the basis of technology, application, route of
administration, and region:
Antisense
& RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)
- RNA
Interference
- siRNA
- miRNA
- Antisense
RNA
Antisense
& RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)
- Oncology
- Cardiovascular
- Respiratory
Disorders
- Renal
Diseases
- Neurodegenerative
Disorders
- Genetic
Disorders
- Infectious
Diseases
- Other
Antisense
& RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million,
2014 - 2025)
- Pulmonary
Delivery
- Intravenous
Injections
- Intradermal
Injections
- Intraperitoneal
Injections
- Topical
Delivery
- Other
Delivery Methods
Antisense
& RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Middle
East & Africa
- South
Africa
Access
Press Release By Grand View Research: www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment